Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Researchers have shown unprecedented control of SIV replication and decay of viral reservoirs by combining a stringent model of infection with the interruption of antiretroviral therapy (ART). The ...

In a session at AIDS 2024, the International AIDS Conference, global leaders and community advocates gathered to discuss why ...

Radiant Biotherapeutics, whose labs are located in Toronto, aims to use the financing to pursue its signature technology, an ...

Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.

In a report released on September 11, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a sneak peek of his panel discussion at this Thursday’s AI Deciphered summit, Merck’s digital privacy director ... and ViiV’s recent activation around HIV awareness in the South.

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...